Home Visit
Upload
.png)
JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR
51+ booked in last 3 days
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 1 Week
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
JAK2 Mutation Test Overview
The JAK-2 (Janus kinase 2) mutation, specifically the V617F variant, detected by Real-Time PCR, is notably associated with myeloproliferative disorders, collectively known as chronic myeloproliferative disorders (CMPD). This genetic mutation plays a pivotal role in the dysregulation of hematopoietic stem cell proliferation, leading to the overproduction of blood cells. Real-Time PCR, a highly sensitive molecular diagnostic technique, enables the detection of the JAK-2 V617F mutation in a patient's genomic DNA, aiding in the diagnosis and classification of CMPDs such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Identifying the JAK-2 mutation by Real-Time PCR holds significant clinical relevance, helping clinicians tailor treatment strategies and monitor disease progression, ultimately improving the management of patients with these hematological disorders.
JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR with a clear pricing structure.
The JAK-2 Mutation (CMPD) (V617F) ,Real-Time PCR Price in Mumbai is ₹ 6,800 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
This test measures the presence of a specific genetic mutation in the JAK-2 gene called V617F. This mutation is commonly associated with Polycythemia vera, Myelofibrosis, and Essential thrombocythemia. Detecting this mutation helps diagnose and monitor these blood disorders.
This test is done for the following reasons:
- To diagnose and monitor Polycythemia vera, Myelofibrosis, and Essential thrombocythemia
- To evaluate the effectiveness of treatment for these blood disorders
- To identify individuals at risk for developing these conditions
- To aid in making treatment decisions based on the presence or absence of the JAK-2 V617F mutation
Your doctor may recommend this test if you have:
- Symptoms suggestive of Polycythemia vera, Myelofibrosis, or Essential thrombocythemia
- Abnormal complete blood count results that indicate a possible blood disorder
- A family history of these blood disorders
- A previous diagnosis of these conditions and need to monitor treatment effectiveness
The normal range for this test is the absence of the JAK-2 V617F mutation. If the mutation is detected, it suggests the presence of Polycythemia vera, Myelofibrosis, or Essential thrombocythemia. Abnormal results require further evaluation and discussion with your doctor to determine the best course of action.
During this test:
- A small sample of your blood will be collected using a needle
- The blood sample will be sent to a laboratory for analysis
- Real-Time PCR technique will be used to detect the presence or absence of the JAK-2 V617F mutation
To prepare for this test:
- No special preparations are usually required
- You can eat and drink normally before the test
- Reach out to your healthcare provider about any specific requirements and medications you are taking as they may affect the test results
Other tests that may be ordered alongside the JAK-2 Mutation (CMPD) RT PCR test include:
- Complete Blood Count (CBC): Measures the levels of different blood cells and helps in diagnosing blood disorders
- Bone Marrow Biopsy: Provides detailed information about the bone marrow, aiding in the diagnosis and monitoring of blood disorders
- JAK-2 V617F mutation test
- JAK2 mutation analysis
Polycythemia vera, Myelofibrosis, and Essential thrombocythemia are three blood disorders characterised by abnormal production and function of blood cells. These conditions can lead to complications such as blood clots, bleeding, and an enlarged spleen.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
1707898101.webp)
WhatsApp